Effects of omega-3 polyunsaturated fatty acid supplementation on parameters of glycaemic control in people with type 1 diabetes: a double-blind, randomised, placebo-controlled trial

L.L. O’Mahoney\textsuperscript{1}, A.M. Alobaid\textsuperscript{2}, R.A. Ajjan\textsuperscript{3}, K.M. Birch\textsuperscript{4}, N.M. Orsi\textsuperscript{5}, G. Mappa\textsuperscript{5}, M. Holmes\textsuperscript{2}, P. Ho\textsuperscript{2}, A. Stavropoulos-Kalinoglou\textsuperscript{1}, O.J. Price\textsuperscript{1} and M.D. Campbell\textsuperscript{2}

\textsuperscript{1}Carnegie School of Sport, Leeds Beckett University, Leeds, UK,
\textsuperscript{2}School of Food Science & Nutrition, University of Leeds, Leeds, UK,
\textsuperscript{3}School of Medicine, University of Leeds, Leeds, UK,
\textsuperscript{4}School of Biomedical Sciences, University of Leeds, Leeds, UK and
\textsuperscript{5}Leeds Institute of Cancer & Pathology, St James’s University Hospital, Leeds, UK

The effect of omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation on glycaemic control in T1D remains unclear\textsuperscript{4). Additionally, the effects of n-3 PUFA on postprandial glucose control in T1D are unknown. Here, we report the effect of 6-month supplementation with a daily high-dose-bolus of n-3 PUFA on parameters of glycaemic control in people with T1D.

For this double-blind, randomized, placebo-controlled trial, individuals with T1D (n = 18; males: 14; 35 ± 15 years; BMI: 26.6 ± 5.2 kg/m\textsuperscript{2}; glycated haemoglobin (HbA\textsubscript{1c}): 59 ± 13 mmol/mol\textsuperscript{-1} [7.5 ± 3.3%]), were randomly allocated in a 1:1 ratio to receive either 3.3 g/day of encapsulated n-3 PUFA or placebo (PLA) consisting of an encapsulated dose of 3.0 g/day corn oil for 6-months. Venous blood samples were obtained at baseline, and 6-months, to determine HbA\textsubscript{1c}, fasting plasma glucose (FPG), and postprandial glucose responses (PPGR) to a standardised mixed-meal tolerance test assessed by area under the curve over a 4-hour period. Fatty acids were measured in erythrocyte membranes by gas chromatography with n-3 PUFA index (O3I) calculated as eicosapentaenoic acid plus docosahexaenoic acid. Paired-samples \textit{t} tests were used to compare intragroup mean differences with statistical significance set at \(p \leq 0.05\). Data are presented as mean ± SD.

In the n-3 PUFA group, baseline O3I increased from 4.97 ± 0.98\% to 8.24 ± 1.52\% after 6-months (\(p < 0.001\)). O3I in PLA did not change (baseline: 4.31 ± 1.22\% vs. 6-months: 4.58 ± 1.59\%; \(p = 0.256\)). In the n-3 PUFA group, the mean difference between baseline and 6-months for HbA\textsubscript{1c} (-3.89 ± 6.05 mmol/mol\textsuperscript{-1}; \(p = 0.090\)), FPG (-1.04 ± 2.82 mmol/L\textsuperscript{-1}; \(p = 0.301\)), and PPGR (-607.03 ± 2014.63 mmol/L\textsuperscript{-1}/min\textsuperscript{-1}; \(p = 0.392\)) did not significantly differ. Similar findings were observed in the PLA group; HbA\textsubscript{1c} (\(p = 0.208\)), FPG (\(p = 0.624\)), and PPGR (\(p = 0.966\)). Overall, no safety issues arose during administration of n-3 PUFA or PLA.

Supplementation with a daily high-dose-bolus of n-3 PUFA for 6-months did not modulate HbA\textsubscript{1c}, FPG, or PPGR to a mixed-meal tolerance test in people with T1D. These findings do not support the use of n-3 PUFA supplementation as an adjunct therapy in the management of T1D.